You suffered damages as a result of these complications, such as medical expenses, lost wages, or pain and suffering
The glucagon receptor component of retatrutide may further modulate these effects, as glucagon is known to influence gut motility
PMC (PubMed Central)
They were initially developed to manage type 2 diabetes, but are now being explored for a broader range of uses, most popularly, in weight management but also importantly, in cardiovascular health
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
